SCHEMBL18137344

SCHEMBL18137344

N=[N+]=Nc1ccc(/C=C/c2ccc(O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 2/20 0.48
▸ LCK P06239 1/20 0.48
▸ APP P05067 6/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ MAPT P10636 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ LMNA P02545 3/20 0.47
▸ TP53 P04637 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ CYP2C9 P11712 3/20 0.47
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA3 P07451 2/20 0.47
▸ CA4 P22748 2/20 0.47
▸ CA6 P23280 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17826832 0.87 PTGS1 (0.57) NQO2LCKAPPKDM4EALDH1A1
SCHEMBL18130122 0.80 NQO2 (0.48) NQO2LCKAPPKDM4EALDH1A1
SCHEMBL18130123 0.80 NQO2 (0.48) NQO2LCKAPPKDM4EALDH1A1
SCHEMBL21242218 0.76 MEN1 (0.58) NQO2LCKAPPKDM4EALDH1A1
SCHEMBL9678787 0.75 APP (0.74) NQO2LCKAPPKDM4EALDH1A1
SCHEMBL6266983 0.75 APP (0.74) NQO2LCKAPPKDM4EALDH1A1
Trans-4,4'-Dihydroxystilbene SCHEMBL145659 0.75 APP (0.74) NQO2LCKAPPKDM4EALDH1A1
SCHEMBL6266987 0.75 APP (0.74) NQO2LCKAPPKDM4EALDH1A1
SCHEMBL6266989 0.75 APP (0.74) NQO2LCKAPPKDM4EALDH1A1
Trans-4,4'-Dihydroxystilbene SCHEMBL491346 0.75 APP (0.74) NQO2LCKAPPKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 — — US disclosed
WO-2016164531-A2 FORMULATION AND PROCESS FOR MODULATING WOUND HEALING BioMendics, LLC (US) 2016-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB NQO2 3151/4885LCK 4119/4885APP 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback